Reduced FXI activity is associated with adverse clinical and echocardiographic profiles in advanced HF. These findings support a potential biomarker or cardioprotective role for FXI and call for caution in applying FXI-targeted therapies in this population.
Mansour et al. (Mon,) studied this question.